The cannabis rescheduling process to Schedule III under the Controlled Substances Act advanced into its final rulemaking phase, per a Department of Justice statement on April 15 following DEA review of over 43,000 public comments submitted after the May 2024 proposed rule. HHS's August 2023 scientific recommendation initiated the shift from Schedule I, but President Trump's December 2025 executive order directed Attorney General Pam Bondi to complete it amid advisor frustrations over delays tied to legal validation. Democratic Rep. Steve Cohen urged a timeline update from Bondi and DEA Administrator Terry Cole on March 27, while Trump reportedly favors interim AG Todd Blanche signing the final order. Traders eye imminent publication or shifts from bureaucratic holdups, with a Medicare-linked CBD pilot hearing scheduled for April 20.
Polymarket verilerine atıfta bulunan deneysel AI tarafından oluşturulmuş özet. Bu bir işlem tavsiyesi değildir ve bu piyasanın nasıl çözümlendiğinde hiçbir rolü yoktur. · Güncellendi$308,391 Hac.

30 Haziran
13%

31 Aralık
49%
$308,391 Hac.

30 Haziran
13%

31 Aralık
49%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Piyasa Açıldı: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The cannabis rescheduling process to Schedule III under the Controlled Substances Act advanced into its final rulemaking phase, per a Department of Justice statement on April 15 following DEA review of over 43,000 public comments submitted after the May 2024 proposed rule. HHS's August 2023 scientific recommendation initiated the shift from Schedule I, but President Trump's December 2025 executive order directed Attorney General Pam Bondi to complete it amid advisor frustrations over delays tied to legal validation. Democratic Rep. Steve Cohen urged a timeline update from Bondi and DEA Administrator Terry Cole on March 27, while Trump reportedly favors interim AG Todd Blanche signing the final order. Traders eye imminent publication or shifts from bureaucratic holdups, with a Medicare-linked CBD pilot hearing scheduled for April 20.
Polymarket verilerine atıfta bulunan deneysel AI tarafından oluşturulmuş özet. Bu bir işlem tavsiyesi değildir ve bu piyasanın nasıl çözümlendiğinde hiçbir rolü yoktur. · Güncellendi
Harici bağlantılara dikkat edin.
Harici bağlantılara dikkat edin.
Sıkça Sorulan Sorular